演題抄録

ポスター

開催概要
開催回
第56回・2018年・横浜
 

食道癌周術期HMGB-1の術後合併症に関する検討

演題番号 : P70-5

[筆頭演者]
演者)山下 俊樹:1 
[共同演者]
川久保 博文:1、前田 祐助:2、真柳 修平:1、福田 和正:1、須田 康一:1、中村 理恵子:1、和田 則仁:1、宮庄 拓:3、北川 雄光:1

1:慶應義塾大学・一般・消化器外科、2:東京都済生会中央病院・外科、3:酪農学園大学・獣医学

 

Although the outcome of treatment of esophageal cancer has been improved, it is sometimes experienced postoperative complications such as pneumonia and anastomotic leakage due to large invasiveness.
We performed a prospective cohort study which collects serum sample of esophageal cancer patients that were supposed to undergo curative esophagectomy. Patients' enrollement was conducted from September 2010 to February 2016. Serum level of High Mobility Group Box 1 (HMGB-1) were measured by Enzyme-Linked Immuno-sorbent Assay (ELISA). Postoperative complications of enrolled patients were analyzed.
One-hundred and seven patients were enrolled in this study. Pneumonia was found in 16 cases (15%) and anastomotic leakage was found in 21 cases (20%). All complications with grade III and more were found in 36 cases (37%) and those with grade II and more were found in 65 cases (61%). The rate of HMGB-1 on 7th postoperatieve day (POD 7) compared to its preoperative level was significantlly high in patients with pneumonia compared to patients without pneumonia (5.74 in patients with pneumonia, 2.50 in patients without pneumonia, p=0.019). The rate of HMGB-1 on POD 7 compared to its preoperative level was significantlly high in patients with all complications with CD grade III and more compared to patients with all complications with CD grade II and less (4.14 (CD grade III and more), 1.99 (CD grade II and less), p=0.017).
The serum HMGB-1 level has a possibility to become a marker of postoperative complications in patients with esophageal cancer that have undergone curative resection.

キーワード

臓器別:食道

手法別:バイオマーカー

前へ戻る